Upregulation of NAC1 is associated with shortened progression-free survival and acquisition of the paclitaxel- and cisplatin-chemoresistance [2, 8, 11, 12, 17], and inhibiting the homodimerization of NAC1 protein can sensitize cancer cells to anticancer agents [18]. Here, NACC1 is linked to cancer.